Precision Neurology Made Practical: Faster Development Through Biomarkers and Real-World Insight

As precision medicine reshapes neurology drug development, sponsors are seeking smarter ways to identify the right patients, integrate biomarkers and generate meaningful evidence across the development lifecycle. Neurology programs often face added complexity because disease progression, patient heterogeneity and endpoint selection can make study design and development decisions more difficult.

This webinar explores how precision neurology strategies can help address these challenges by connecting patient identification approaches, biomarker strategies and real-world evidence across early development, clinical trials and post-launch planning. Attendees will learn how integrated evidence strategies can improve study efficiency, support more informed decision-making and help reduce development risk.

The featured speakers will discuss how biomarkers, digital insights and real-world evidence can work together to deepen understanding of disease progression, refine trial design and support commercialization planning. The session will also examine how these approaches can help sponsors identify appropriate patient populations, evaluate meaningful outcomes and generate evidence that supports development and market access goals.

Register for this webinar to learn how precision neurology can help accelerate neurology drug development through biomarkers, patient identification and real-world insight.

Speakers

(Rachel) Zhe Rachel Angerer, Senior Director, Patient First Digital Solutions, PPD Clinical Research Services, Thermo Fisher Scientific

Rachel is the Head of Global Patient Recruitment Marketing at Thermo Fisher Scientific. She leads the team to accelerate clinical trial enrolment by finding and retaining quality patients in the most cost-efficient way. Her current focus is on scaling AI-driven Omnichannel capabilities and utilizing connections to real-world-data for higher precision and conversions.

As an expert in end-to-end marketing strategy and operations, Rachel’s career has spanned Fortune 100 companies across healthcare and financial services. She builds marketing teams and platforms to modernize targeting, creative, channel mix and partnership ecosystems from direct-to-consumer to B2B2C. She is driven by the mission to make people’s lives easier and better at scale. Rachel is multilingual and holds an MBA in Finance from the Zicklin School of Business in the US, and a BA in International Trade from Sichuan University, China.

Message Presenter

(TJ) Tracy Jerome Stalvey, MPH, MBA, VP, Therapeutic Lead – Epilepsy, Sleep & Neuroinflammatory Disorders, PPD Clinical Research Services, Thermo Fisher Scientific

TJ brings more than 25 years of leadership experience across pharmaceutical, biotechnology, CRO and medical device organizations, with deep expertise in global neuroscience drug development. His background includes significant work in epilepsy and other CNS disorders, and he has led programs from early development through regulatory submission and commercialization.

TJ has held senior leadership roles at UCB Biosciences, Neurelis, Elligo Health Research and NX Development Corporation. His experience supporting successful filings, launches and growth strategies will be a strong asset moving forward. He holds an MBA from Georgia Institute of Technology and an MPH from the University of Alabama at Birmingham.

Message Presenter

David Scott, PhD, Vice President, Medical and Scientific Affairs, Neuroscience, Clario, Inc.

David Scott, PhD, is the Vice President of Medical and Scientific Affairs at Clario. His aim is to facilitate drug development through standardized measurement of the neural correlates of neurodegenerative and other centrally mediated diseases. As a student at Johns Hopkins University and the University of Michigan, he employed multi-modal imaging approaches, including dynamic PET and functional MRI to study the neurobiology of placebo analgesia. At Omneuron, he developed real-time fMRI applications aimed at treating chronic pain, depression and addiction.

Since joining Clario in 2012, David has focused on the standardized assessment of brain MRI and PET endpoints for eligibility, safety monitoring and therapeutic efficacy in neuroscience clinical trials. He works with Radiologists, Physicists, Software Engineers and Operational Specialists on the design, execution, analysis and interpretation of clinical trial imaging data. His motivation is to facilitate neuroimaging to accelerate the delivery of therapeutic benefits to patients around the world.

Message Presenter

Ariel Berger, MPH, Executive Director, Integrated Solutions, Real World Evidence, PPD Clinical Research Services, Thermo Fisher Scientific

Ariel Berger, MPH, is an Executive Director, Integrated Solutions, US Database Analytics in the Real-World Data & Scientific Solutions (RWD&SS) group at PPD™ Evidera™, part of Thermo Fisher Scientific and is located in Massachusetts. In Mr. Berger’s current position, he helps lead the Database Analytics Business Unit, contributing to internal processes, staff development and training, and development of new customer offerings. He also designs and leads/advises on various RWE and health economics studies, often involving complex methodologies and hybrid designs and disciplines, and strategic initiatives, such as data landscaping and evidence generation planning. Prior to joining Evidera, he was a Senior Consultant with Policy Analysis Inc. for approximately 13 years, during which time he led numerous outcomes research studies, including retrospective database analyses; developed health economic models (both budgetary impact and cost-effectiveness models); performed literature reviews; and prepared product dossiers.

Mr. Berger has experience across a wide range of therapeutic areas, including but not limited to pulmonary arterial hypertension, infectious diseases, oncology, cardiovascular disease, osteoarthritis, neuropathic pain, fibromyalgia, migraine headache, mental health disorders, end-stage renal disease and ostomy/incontinence care. His related work has been published in peer-reviewed journals, including Surgical Infections, Pain Practice, Journal of Health and Productivity, American Journal of Managed Care, Infection Control and Hospital Epidemiology, Annals of Pharmacotherapy and BMC Pulmonary Medicine. His work has been presented at conferences such as the American Thoracic Society (ATS), the European Society of Clinical Microbiology and Infectious Diseases (ECMID), the American Society of Nephrology (ASN), the Infectious Diseases Society of America (IDSA) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Mr. Berger has an MPH in Epidemiology and Biostatistics from the Boston University School of Public Health and a BA from Syracuse University.

Message Presenter